Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient

Pulmonology. 2020 Jan-Feb;26(1):49-50. doi: 10.1016/j.pulmoe.2019.05.002. Epub 2019 Aug 7.

Authors

I Domingues¹, S Cedres², A Callejo², A Vivancos³, A Martinez-Marti², E Felip²

Affiliations

¹ Medical Oncology Department, Portuguese Institute of Oncology of Coimbra, Coimbra, Portugal. Electronic address: isabelcpdomingues@gmail.com.
² Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
³ Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

PMID: 31401029
DOI: 10.1016/j.pulmoe.2019.05.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

AMP-Activated Protein Kinase Kinases
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / metabolism
Carcinoma, Non-Small-Cell Lung / therapy*
DNA Mutational Analysis
DNA, Neoplasm / genetics*
DNA, Neoplasm / metabolism
Female
Humans
Immunotherapy / methods*
Lung Neoplasms / genetics
Lung Neoplasms / metabolism
Lung Neoplasms / therapy*
Middle Aged
Mutation*
Protein Serine-Threonine Kinases / genetics*
Protein Serine-Threonine Kinases / metabolism
Proto-Oncogene Proteins p21(ras) / genetics*
Proto-Oncogene Proteins p21(ras) / metabolism

Substances

DNA, Neoplasm
KRAS protein, human
Protein Serine-Threonine Kinases
STK11 protein, human
AMP-Activated Protein Kinase Kinases
Proto-Oncogene Proteins p21(ras)